Quinoxaline derivatives show very interesting biological properties such as antibacterial (1), antiviral (2), antifungal (3), anthelmintic (4) and insecticidal (5). They were proven to be efficient anticancer agents when tested against several cell lines. Several quinoxaline derivatives were reported to be potent and highly selective epidermal growth factor receptor tyrosine kinase inhibitors (7). On the other hand, thioureido sulfonamide derivatives were reported to show significant anticancer activity by acting as carbonic anhydrase inhibitors (8). In the light of these facts and as a continuation of our previous work (9-12), we planned to synthesize novel thioureido sulfaquinoxaline Sulfonamides and quinoxaline derivatives possess many types of biological activities and have been recently reported to show substantial antitumor activity. This paper reports the synthesis of novel thioureido sulfaquinoxaline derivatives. All the newly synthesized compounds were evaluated for their in vitro anticancer activity against a human liver cell line (HEPG2) and showed higher activity than the reference drug doxorubicin. 4-(3-(4-Ethylben- The most potent compounds 9, 10 and 11 were evaluated as radiosensitizing agents by subjecting the compounds to g-irradiation (8 kGy).
derivatives hoping that the new compounds might show significant anticancer activity and to study their structure-activity relationships. Moreover, this research was also aimed to evaluate the new compounds for their in vitro anticancer activity in combination with g-irradiation.
EXPERIMENTAL
Melting points are uncorrected and were determined on a Stuart melting point apparatus (Stuart Scientific, UK). Elemental analyses (C, H, N) were performed on a Perkin-Elmer 2400 analyzer (Perkin-Elmer, USA) at the Microanalytical Laboratories of the Faculty of Science, Cairo University. All compounds were within ±0.4 % of theoretical values. The IR spectra (KBr) were measured on a Shimadzu IR 110 Spectrophotometer (Shimadzu, Japan), 1 H NMR and 13 C NMR spectra were obtained with a Bruker proton NMR-Avance 300 instrument (300 MHz) (Bruker, Germany), in DMSO-d 6 as a solvent, using tetramethylsilane (TMS) as internal standard. Mass spectra were run using an HP Model MS-5988 (Hewlett Packard, USA). All reactions were monitored with a thin layer chromatography using precoated aluminum sheets (Silica gel Merck 60 F 254 ) and were visualized with a UV lamp (Merck, Germany). All chemicals (sulfaquinoxaline and doxorubicin) were commercially supplied from Sigma-Aldrich (USA). (2) . -To a suspension of sulfaquinoxaline 1 (3 g, 0.01 mol) in water (30 mL), thiophosgene (1 mL, 0.01 mol) was added and the reaction mixture was stirred for 1 h until red color of the thiophosgene disappeared and a white precipitate was formed. The precipitate was filtered off and washed with water to give compound 2. (3) . -A mixture of 2 (0.342 g, 0.01 mol) and 2-aminopyridine (0.094 g, 0.01 mol) in dimethylformamide (DMF) (20 mL) containing 3 drops of triethylamine (TEA), was refluxed for 5 h. The solid obtained was precipitated while hot and filtered to give compound 3. (4) . -A mixture of 2 (0.342 g, 0.01 mol) and 2-amino-5-chloropyridine (0.128 g, 0.001 mol) in DMF (20 mL), containing 3 drops of TEA, was refluxed for 5 h. The solid obtained was precipitated while hot and filtered to give compound 4. (5) . -A mixture of 2 (0.342 g, 0.001 mol) and 2-amino-5-bromopyridine (0.173 g, 0.001 mol) in DMF (20 mL), containing 3 drops of TEA, was refluxed for 5 h. The solid obtained was precipitated while hot and filtered to give compound 5. (6) . -The mixture of 2 (0.342 g, 0.01 mol) and p-bromoaniline (0.171 g, 0.001 mol) in dioxane (20 mL), with 3 drops of TEA, was refluxed for 1 h, the solid obtained was precipitated when cold and filtered to give compound 6.
Syntheses 4-Isothiocyanato-N-quinoxaline-2-yl-benzenesulfonamide

4-(3-Pyridin-2-yl-thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide
4-(3-(5-Chloropyridin-2-yl)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide
4-(3-(5-Bromopyridin-2-yl)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide
4-(3-(4-Bromophenyl)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide
4-(3-(4-Fluorophenyl)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide (7)
. -A mixture of 2 (0.342 g, 0.01 mol) and p-fluoroaniline (0.111 g, 0.001 mol) in dioxane (20 mL), with 3 drops of TEA, was refluxed for 1 h. The solid obtained was precipitated when cold and filtered to give compound 7. (8) . -A mixture of 2 (0.342 g, 0.001 mol) and p-chloroaniline (0.127 g, 0.001 mol) in dioxane (20 mL), with 3 drops of TEA, was refluxed for 1 h, the solid obtained was precipitated while hot and filtered to give compound 8. (9) . -A mixture of 2 (0.342 g, 0.001 mol) and benzocaine (0.165 g, 0.001 mol) in dioxane (20 mL), with 3 drops of TEA, was refluxed for 5 h. The solid obtained was precipitated when hot and filtered to give compound 9. (10) . -A mixture of 2 (0.342 g, 0.01 mol) and sulfapyridine (0.233 g, 0.01 mol) in DMF (20 mL), with 3 drops of TEA, was refluxed for 5 h. The solid was precipitated when hot and filtered to give compound 10.
4-(3-(4-Chlorophenyl)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide
4-(3-(4-Carbethoxy)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide
-A mixture of 2 (0.342 g, 0.001 mol) and sulfathiazole (0.239 g, 0.001 mol) in DMF (20 mL), with 3 drops of TEA, was refluxed for 5 h. The solid was precipitated when hot and filtered to give compound 11.
In vitro anticancer screening
The human tumor cell line (HEPG2) was obtainedfrom the National Cancer Institute, Cairo, Egypt. Irradiation was performed using a Gamma cell-40 ( 60 Co) source Color intensity was measured in an ELISA reader (SPR-960B Sunostick Medical Technology, UK). Negative control was added using cell lines with the solvent without the drug. The relation between the surviving fraction and drug concentration was plotted to get the survival curve of each tumor cell line after a specified time. The concentration required for 50 % inhibition of cell viability (IC 50 ) was calculated and compared with the reference drug doxorubicin and the results are given in Table III .
Radiosensitizing activity
The most potent compounds resulting from the in vitro anticancer screening (compounds 9, 10 and 11) were selected in order to evaluate their in vitro anticancer activity in combination with g-radiation. This study was conducted to evaluate the ability of these compounds to enhance the cell killing effect of g-radiation. Negative control was added using cell lines with the solvent without the drug and radiation alone. Cells were subjected to a single dose of g-irradiation at a dose level of 8 kGy with a dose rate of 2 kGy min -1 . The surviving fractions were expressed as the mean ± standard error. The results were analyzed using the 1-way ANOVA test and are given in Table IV. RESULTS AND DISCUSSION Chemistry 4-Isothiocyanato-N-quinoxaline-2-yl-benzene sulfonamide 2 was prepared by the reaction of N-quinoxaline-2-yl-benzenesulfonamide with thiophosgene as reported earlier (14) . Compound 2 was used to prepare different sulfonamide derivatives by incorporating different biologically active moieties. Compound 2 reacted with 2-aminopyridine to obtain the corresponding thioureido derivative 3, while its interaction with 2--aminopyridine, 2-amino-5-chloropyridine and 2-amino-5-bromopyridine yielded compounds 4 and 5, respectively (Scheme 1).
The isothiocyanato derivative 2 was further reacted with different aniline derivatives to obtain the corresponding thioureido derivatives. Thus, its interaction with 4-bromoaniline, 4-fluoroaniline, 4-chloroaniline and benzocaine yielded compounds 6, 7, 8, and 9, respectively.
Another sulfonamide molecule was incorporated into isothiocyanate 2 through its reaction with sulphapyridine and sulphathiazole and compounds 10 and 11 were obtained, respectively (Scheme 1).
In vitro anticancer activity
Newly synthesized compounds were evaluated for their in vitro cytotoxic activity against a human liver cancer cell line (HEPG2). Doxorubicin, one of the most effective anticancer agents, was used as the reference drug. The relationship between the surviving fraction and drug concentration was plotted to obtain the survival curve of the liver cancer cell line. The response parameter calculated was the IC 50 value, which corresponds to the concentration required for 50 % inhibition of cell viability. Table III shows the in vitro anticancer activity of the synthesized compounds, which exhibited significant activity compared to the reference drug. It was found that in the negative control, the solvent had no effect on the cells as the surviving fraction was 1.00, all the tested compounds showed lower IC 50 than doxorubicin (IC 50 = 71.8 mmol L -1 ), with compound 9 (IC 50 = 15.6 mmol L -1 ) being the most potent in this screening. This might be due to incorporation of ethylbenzoate group since the corresponding halogenated compounds 6, 7 and 8 exhibited lower activity (IC 50 = 31.2-39.6 mmol L -1 ). Incorporation of pyridine moiety yielding moderate activity in compound 3 (IC 50 = 30.0 mmol L -1 ) and this activity slightly increased to 27.6 and 28 mmol L -1 , respectively, in compounds 4 and 5 containing halogenated pyridine moieties. Replacement of pyridine with sulfapyridine moiety in compound 10 yielded an increased activity (IC 50 = 26.8 mmol L -1 ) which was also in- 
Radiosensitizing evaluation
The rationale for combining chemotherapy and radiotherapy is mainly based on two ideas, one being spatial cooperation, which is effective if chemotherapy is sufficiently active to eradicate subclinical metastases and if the primary local tumor is effectively treated by radiotherapy. In this regard, no interaction between radiotherapy and chemotherapy is required. The other idea is the enhancement of radiation effects. Cytotoxic agents can enhance radiation effects by direct enhancement of the initial radiation damage by incorporating drugs into DNA, inhibiting cellular repair, accumulating cells in a radiosensitive phase or eliminating radioresistant phase cells, eliminating hypoxic cells or inhibiting the accelerated repopulation of tumor cells. Consequently, the ability of the most active compounds (9, 10 and 11) to enhance the cell killing effect of g-irradiation was studied. From the results given in Tables III and IV , it was concluded that in the negative control, radiation alone had a low effect on the cells, compound 9 showed in vitro cytotoxic activity with the IC 50 value of 15.6 mmol L -1 when the cells were subjected to different concentrations of the compound alone. However, when the cells were subjected to the same concentrations of compound 9 and irradiated with a single dose of g-radiation of 8 kGy, These results point to the conclusion that using a combination of compounds 9, 10 or 11 and ionizing radiation synergistically enhances growth inhibition of liver cancer cells compared to the use of each agent alone.
CONCLUSIONS
The above results allow the conclusion that administration of the tested compounds to the human liver (HEPG2) cell lines showed promising anticancer activity. The most potent compounds being4-(3-(4-ethylbenzoate)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide (9) (IC 50 = 15.6 mmol L -1 ), N-(pyridin-2-yl)-4-(3-(4-(N-quinoxalin-2-yl-sulfamoyl)phenyl)thioureido)benzenesulfonamide (10) (IC 50 = 26.8 mmol L -1 ) and N-(quinoxalin-2-yl)-4-(3-(4-(N-thiazol-2-ylsulfamoyl)phenyl)thioureido)benzenesulfonamide (11) (IC 50 = 24.4 mmol L -1 ). Combining these compounds, at the same concentrations, with radiation enhances their activity. This indicates the importance of a combination therapy for cancer patients to reduce the side effects of both drugs and radiation. 
